Latest 10-Q quarterly reports

Tancheng Group Co., Ltd. reported no revenue for the first quarter of 2026, a 100% decrease from the prior year, due to a strategic shift in business operations.

Local Bounti Corporation reported a 15% increase in sales for Q1 2026, driven by expanded production, though the company continues to face significant operating losses and liquidity concerns.

Immuneering Corporation filed its Form 10-Q for the quarter ended March 31, 2026, detailing its financial performance, ongoing clinical trials, and strategic outlook.

Galectin Therapeutics reports a narrowed net loss for Q1 2026, driven by decreased R&D spending, while continuing to rely on Chairman's credit lines for liquidity.

Sensei Biotherapeutics announces significant increase in operating expenses and net loss for Q1 2026, primarily due to the acquisition of Faeth Therapeutics and associated costs.

Koil Energy Solutions, Inc. announced a significant 56% increase in revenue for the first quarter of 2026, driven by strong performance in lump-sum projects and new customer acquisitions.

Rapid Micro Biosystems, Inc. reported an 11.1% increase in total revenue for the first quarter of 2026, reaching $8.0 million, despite a wider net loss.

Lightstone Value Plus REIT V, Inc. reported a net loss for the first quarter of 2026, driven by a decrease in rental revenues and increased interest expenses, while also undertaking significant financing activities.

Merlin, Inc. reported a 15.4% revenue increase in Q1 2026 to $1.002 million, but net losses widened significantly to $90.4 million due to merger-related costs and increased operating expenses.

ZW Data Action Technologies reports a significant revenue decrease in Q1 2026, driven by economic headwinds and a strategic shift towards AI services.

Traws Pharma reported a significant increase in R&D expenses for Q1 2026, alongside a continued net loss and concerns about its ability to continue as a going concern.

BioXcel Therapeutics reported increased product revenue but a wider net loss in Q1 2026, with ongoing concerns about its ability to continue as a going concern.

Bit Digital Inc. reported a net loss of $150.3 million for Q1 2026, with revenues growing to $27.9 million, driven by cloud and colocation services, while digital asset mining revenue declined.

Future Vision II Acquisition Corp. reports Q1 2026 results, with net income of $418,756, and continues efforts to secure a business combination before its September 13, 2026 deadline.

Digi Power X Inc. reports a significant shift in revenue streams from cryptocurrency mining to AI data center development, with substantial new contracts and strategic investments shaping its future outlook.

StoneBridge Acquisition II Corporation reports Q1 2026 results, with net income driven by trust account interest and dividends, while continuing its search for a business combination.

ARS Pharmaceuticals announced a significant increase in total revenue for the first quarter of 2026, driven by strong product sales of neffy and contributions from collaboration and supply agreements.

Livento Group, Inc. reported a net loss of $379,169 for the first quarter of 2026, with revenues decreasing compared to the prior year period.

Mountain Crest Acquisition Corp. V reports Q1 2026 financials, detailing operational costs and progress towards a business combination.

Translational Development Acquisition Corp. reports net income of $1.33M for Q1 2026, driven by investment income, while continuing its search for a business combination before its June 2026 deadline.

Magellan Copper & Gold Corp. reports increased administrative expenses and a continued net loss for Q1 2026, with a focus on advancing the Ophir Creek Placer Gold Mine.

Allbirds, Inc. reports a significant revenue decline and gross margin contraction in Q1 2026, while simultaneously advancing its strategic pivot towards an Electronics Infrastructure Business following the sale of its footwear assets.

EGH Acquisition Corp. reports Q1 2026 financials, highlighting progress on its business combination with Hecate, which is currently facing a legal challenge that has delayed the closing.

Transportation and Logistics Systems, Inc. reports no revenue for Q1 2026 while advancing a reverse triangular merger with Patriot Glass Solutions.

Sharps Technology, Inc. has adopted a limited duration stockholder rights plan to protect shareholder interests.

TMC reports Q1 2026 financial results and announces a new development contract with Allseas for deep-sea nodule collection.

Royalty Management Holding Corporation reported a significantly increased net loss in Q1 2026, primarily driven by a substantial loss on warrant fair value adjustment, despite revenue growth in environmental services.

Propanc Biopharma reports a net loss of $6.36 million for the third quarter of fiscal 2026 as it continues development of its lead cancer treatment candidate, PRP.

Valion Bio reports Q1 2026 financial results, highlighting its transition to a biopharmaceutical company and the expansion of its CDMO operations in San Antonio.

NexGel reports Q1 2026 financial results, highlighting a net loss of $0.9 million and significant capital raising activities to support its Celularity biomaterials acquisition.